NXGL Stock Overview Manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for NEXGEL Historical stock prices Current Share Price US$3.82 52 Week High US$5.10 52 Week Low US$1.84 Beta 0.61 1 Month Change -0.26% 3 Month Change 29.71% 1 Year Change 68.65% 3 Year Change 57.85% 5 Year Change n/a Change since IPO 8.52%
Recent News & Updates
NEXGEL, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2024 and Fiscal Year 2025 Jan 23
New major risk - Shareholder dilution Jan 16
CEO, President & Director notifies of intention to sell stock Jan 03 NEXGEL, Inc. Announces Chief Financial Officer Changes Jan 02
Independent Director notifies of intention to sell stock Dec 22
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 15 See more updates
NEXGEL, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2024 and Fiscal Year 2025 Jan 23
New major risk - Shareholder dilution Jan 16
CEO, President & Director notifies of intention to sell stock Jan 03 NEXGEL, Inc. Announces Chief Financial Officer Changes Jan 02
Independent Director notifies of intention to sell stock Dec 22
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 15
Price target decreased by 14% to US$6.00 Nov 14
Forecast breakeven date moved forward to 2025 Nov 14 NEXGEL, Inc. has filed a Follow-on Equity Offering. Nov 12
NEXGEL, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Oct 10
NEXGEL, Inc. Appoints Kip Crecca to Its Scientific Advisory Board Oct 04 NEXGEL, Inc. Reiterates Revenue Guidance for the Third Quarter and Fourth Quarter of 2024 NEXGEL, Inc. has filed a Follow-on Equity Offering in the amount of $1.11 million. Aug 13
NEXGEL, Inc. to Report Q2, 2024 Results on Aug 14, 2024 Aug 12
New minor risk - Share price stability Jul 26
NEXGEL, Inc. and Innovative Optics US Initiate Institutional Review Board Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal Jul 19
NEXGEL, Inc. Provides Preliminary Revenue Guidance for the Second, Third and Fourth Quarter of 2024 Jul 09
Price target decreased by 14% to US$6.00 Jul 02
NEXGEL, Inc. to Report Q1, 2024 Results on May 13, 2024 May 11
NEXGEL, Inc., Annual General Meeting, Jun 17, 2024 May 01 NEXGEL, Inc. announced delayed annual 10-K filing
Forecast breakeven date pushed back to 2026 Apr 02
NEXGEL, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 22
NEXGEL, Inc. has filed a Follow-on Equity Offering. Feb 24
NEXGEL, Inc. has filed a Follow-on Equity Offering. Feb 23 NEXGEL, Inc. has filed a Follow-on Equity Offering. Feb 22
NEXGEL, Inc. Announces Intention of Miranda J. Toledano to Resign as a Member of the Board of Directors, Effective as of March 31, 2024 Jan 17
NEXGEL, Inc. Announces Resignation of David Stefansky as Member of the Board of Directors Dec 13
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 16
NEXGEL, Inc. to Report Q3, 2023 Results on Nov 13, 2023 Nov 03
Price target increased by 20% to US$6.00 Nov 01
New major risk - Market cap size Oct 12
New major risk - Market cap size Aug 16
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 16
NEXGEL, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 03
Consensus revenue estimates increase by 62% May 22
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 17
NEXGEL, Inc. to Report Q1, 2023 Results on May 15, 2023 May 10
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 29
NEXGEL, Inc. Announces Directorate and Committee Changes Jan 19
Nexgel Appoints Scott Henry, to Board of Directors and Audit Committee Jan 18
Forecast to breakeven in 2025 Dec 31
NEXGEL, Inc. Launches Turfguard to Treat Painful Turf Burns and Protect Sports-Related Wounds Dec 10
NEXGEL, Inc. (NasdaqCM:NXGL) announces an Equity Buyback for $0.5 million worth of its shares. Dec 08
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 10
NEXGEL, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 03
NEXGEL, Inc. Reports Positive Results from Proof-Of-Concept Study for Its Diclofenac Hydrogel Pain Treatment Oct 26
Nexgel, Inc. Develops New Hydrogel Patch to Treat Amblyopia Oct 21
NEXGEL, Inc. Announces SAGE Journals Publishes New Data Revealing SilverSeal Hydrogel Dressing Improves Postsurgical Scarring Oct 04
NEXGEL, Inc. Announces Scientific Advisory Board Appointments Sep 30
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 12
NEXGEL, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Aug 05
NEXGEL Launches Medagel Hydroliner Pro Pads for Eyelash Protection During Cosmetic Extensions Service Jul 27
NEXGEL, Inc., Annual General Meeting, Aug 30, 2022 Jul 19
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 13 NEXGEL, Inc. to Report Q1, 2022 Results on May 12, 2022 May 10
High number of new and inexperienced directors Apr 27
NexGel: Old Wine In A New Bottle Jan 30
NEXGEL, Inc. Announces the Launch of MEDAGEL ClearComfort Hydrogel Patch Jan 13
NEXGEL, Inc. has completed an IPO in the amount of $14.235131 million. Dec 23
High number of new and inexperienced directors Dec 18 Shareholder Returns NXGL US Medical Equipment US Market 7D 14.7% -0.08% -0.8% 1Y 68.7% 13.6% 22.7%
See full shareholder returns
Return vs Market: NXGL exceeded the US Market which returned 22.7% over the past year.
Price Volatility Is NXGL's price volatile compared to industry and market? NXGL volatility NXGL Average Weekly Movement 12.1% Medical Equipment Industry Average Movement 8.8% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.2%
Stable Share Price: NXGL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NXGL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Founded Employees CEO Website 2009 19 Adam Levy nexgel.com
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments, Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications under the MedaGel brand; and beauty and cosmetic solutions, such as wrinkle and skin cream applications under the LumaGel Beauty brand name.
Show more NEXGEL, Inc. Fundamentals Summary How do NEXGEL's earnings and revenue compare to its market cap? NXGL fundamental statistics Market cap US$28.72m Earnings (TTM ) -US$3.53m Revenue (TTM ) US$6.73m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NXGL income statement (TTM ) Revenue US$6.73m Cost of Revenue US$4.60m Gross Profit US$2.13m Other Expenses US$5.66m Earnings -US$3.53m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.47 Gross Margin 31.61% Net Profit Margin -52.44% Debt/Equity Ratio 21.1%
How did NXGL perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/02 09:42 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources NEXGEL, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason McCarthy Maxim Group Nazibur Rahman Maxim Group
Show 0 more analysts 
